Literature DB >> 28367848

TNF Receptor 1/2 Predict Heart Failure Risk in Type 2 Diabetes Mellitus Patients.

Zhang Ping1, Ma Aiqun, Li Jiwu, Shao Liang.   

Abstract

Inflammation plays an important role in heart failure and diabetes mellitus. Traditional serum markers have limited predictive value in heart failure and diabetes. TNFR1 and TNFR2 (TNFR1/2) have been proven to be strongly associated with heart failure and diabetes complications. This study aimed to assess the association of sTNFR1 and sTNFR2 levels and incidental HF risk in diabetes patients.We detected the mRNA, protein, and serum expression of TNFR1/2, their downstream signaling pathway protein NF-kB, and JNK expression and some traditional serum inflammatory markers in a heart failure group without diabetes mellitus or abnormal glucose tolerance (n = 84), a diabetes mellitus group without heart failure (n = 86), and a heart failure with diabetes mellitus group (n = 86).TNFR1/2 were significantly higher in patients with heart failure and diabetes mellitus based on mRNA expression to protein expression and serum expression. However, there were no differences in mRNA, protein, and serum levels of TNFR1/2 between the HF group and DM group. Furthermore, there were no differences between the groups in some traditional serum inflammatory markers.This study demonstrated higher expressions of TNFR, NF-kB, and JNK in patients with heart failure and diabetes mellitus. Compared with traditional serum markers, TNFR1 and TNFR2 are associated with heart failure risk in type 2 diabetes mellitus patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28367848     DOI: 10.1536/ihj.16-236

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  8 in total

Review 1.  Redefining biomarkers in heart failure.

Authors:  Michele Correale; Ilenia Monaco; Natale Daniele Brunetti; Matteo Di Biase; Marco Metra; Savina Nodari; Javed Butler; Mihi Gheorghiade
Journal:  Heart Fail Rev       Date:  2018-03       Impact factor: 4.214

2.  [Dihydromyricetin improves cardiac insufficiency by inhibiting HMGB1 in diabetic rats].

Authors:  S Liu; Q Liu; Q Peng; Y Zhang; J Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-05-20

Review 3.  Role of cytokines and inflammation in heart function during health and disease.

Authors:  Monika Bartekova; Jana Radosinska; Marek Jelemensky; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

4.  The Effect of Curcumin Nanoparticles on Cisplatin-Induced Cardiotoxicity in Male Wistar Albino Rats.

Authors:  Yasser A Khadrawy; Eman N Hosny; Mayada M El-Gizawy; Hussein G Sawie; Heba S Aboul Ezz
Journal:  Cardiovasc Toxicol       Date:  2021-02-06       Impact factor: 3.231

5.  The association between TNFR gene polymorphisms and the risk of Hepatitis B Virus-Related Liver Diseases in Chinese population.

Authors:  Liping Ma; Siyuan Chen; Xiaohuan Mao; Yu Lu; Xiaolian Zhang; Xianjun Lao; Xue Qin; Shan Li
Journal:  Sci Rep       Date:  2018-06-18       Impact factor: 4.379

6.  Metformin Monotherapy Downregulates Diabetes-Associated Inflammatory Status and Impacts on Mortality.

Authors:  Anteneh Mehari Tizazu; Ma Shwe Zin Nyunt; Olivier Cexus; Koolarina Suku; Esther Mok; Chin Hui Xian; Joni Chong; Crystal Tan; Wilson How; Sandra Hubert; Emilie Combet; Tamas Fulop; Tze Pin Ng; Anis Larbi
Journal:  Front Physiol       Date:  2019-05-21       Impact factor: 4.566

7.  Toll-Like Receptors/TNF-α Pathway Crosstalk and Impact on Different Sites of Recurrent Myocardial Infarction in Elderly Patients.

Authors:  Xia Li; Dianxuan Guo; Ying Chen; Youdong Hu
Journal:  Biomed Res Int       Date:  2022-04-05       Impact factor: 3.411

8.  Clinical Significance of TNFRSF1A36T/C Polymorphism in Cachectic Patients with Chronic Heart Failure.

Authors:  Grzegorz Sobieszek; Tomasz Powrózek; Aneta Skwarek-Dziekanowska; Teresa Małecka-Massalska
Journal:  J Clin Med       Date:  2021-03-05       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.